WHO Register of non-State actors

Disclaimer:

Information regarding a non-State actor, contained in the section “Non-State Actors Profiles” in the Register, has been provided by that non-State actor itself, and the accuracy and completeness of such information is the sole responsibility of that non-State actor, not WHO. In turn, information in the sections “WHO’s Engagement” and “Non-State Actors in Official Relations” has been provided by WHO, subject to certain conditions. All access and use of any section of the Register is governed by the Terms and Conditions of Use.

Overview

Official name

International Federation of Biomedical Laboratory Science

Acronym (if applicable)

IFBLS

Short self description

IFBLS is a global federation of biomedical laboratory scientists/technologists from 40 countries around the world. The IFBLS mission is to promote the development of laboratory professionals and laboratory medicine through education and partnerships.

Website

http://ifbls.org

Web link to health relevant activities

Parent entity (if applicable)

The entity you represent is indicated as a parent of the following entities in the Register:

N / A

Date submitted

26 Aug 2024 06:44:39 PM

General information

Name

Official name

International Federation of Biomedical Laboratory Science

Acronym (if applicable)

IFBLS

Commonly used name (if applicable)

Names in other official languages (if applicable) Name Abbreviation

International Federation of Biomedical Laboratory Science

IFBLS

Former name

Short self description

Address Contact

Address 1

33 Wellington Street North

Address 2

Address 3

Town/City

Hamilton

State/Region

Ontario

Postal code

L8R 1M7

Country

Canada

Email (generic)

communications@ifbls.org

Related links

Website

http://ifbls.org

Governance

Legal status

Not for Profit

Year established

1954

Governance structure

Description of main decision making bodies (e.g. board, board of directors, executive board, executive committee, etc).

Name of body

Board of Directors

Composition and current list of members Name Function Affiliation

Alan Wainwright

Past-President

Retired, Institute of Biomedical Science, United Kingdom

Marie Culliton

President

Chief Medical Scientist, The National Maternity Hospital, Ireland

Gabriella Lillsunde Larsson

President-Elect

Associate Professor, School of Health Sciences Orebro University, Sweden

Hassan Aziz

Board Director

Past-President, American Society for Clinical Laboratory Science

Marie Klement

Board Director

Past-President, Canadian Society for Medical Laboratory Science

Godswill C. Okara

Board Director

Registrar & Secretary General, WAPCMLS

Ki-Jong Rhee

Board Director

Professor, Yonsei University, Dept. Biomedical Laboratory Science

David Wells

Board Director

CEO, Institute of Biomedical Science, United Kingdom

Functions

The Board of Directors of IFBLS are individuals nominated and elected from the Association Members of the Corporation. Board of Directors shall be constituted as outlined in Section 5 of the By-Laws. Within the Board of Directors, the Officers of IFBLS are the President, President-Elect and the Past-President, who constitute the Management Committee.
By seeking election to the Board of Directors, Directors have agreed to donate considerable time and effort to the organisation.
Directors are volunteers and do not receive remuneration for the time and effort which they contribute to the organisation. Directors honor the responsibilities and duties of the Board by active participation at Board and Committee meetings and by active involvement in projects and assignments with reports as required.
Directors hold shared responsibility for carrying out the objectives of IFBLS according to the By-Laws, Operational Action Plan and agreements of the GAD.
Directors report to the President and are assigned to committees and projects by the President or the Management Committee
The Board in total is responsible for carrying out the financial decisions of the GAD.

Name of body

Composition and current list of members Name Function Affiliation

Functions

General Assembly

Does the entity have a General Assembly of members or a similar body?

Yes

Name

General Assembly of Delegates

Composition

All Association Members of IFBLS

Functions

At the formal GAD the elected Board of Directors report to Association Members on the IFBLS’s progress since the last meeting and receive feedback from the delegates. The financial report, budget and reports from Open Forum are presented. A new Board of Directors is elected every two years at the GAD.

Financial information

Latest available annual income (month/year)

From

January

2023

December

2023

Annual income (USD)

92,362

Latest available assets (month/year)

As of

December

2023

Total assets (USD)

504,110

Income sources (in USD)

Income source Income type

Private sector entities (including business associations)

Philanthropic foundations

NGOs, academic institutions

Government entities, intergovernmental organizations, including UN

General public, individuals

Total

Sales of goods and services *

Grants / Donations

In-kind donations

Membership fees

76,439

Investment income

15,923

Others

Total

92,362

* income from congresses / conferences should be listed under Sales of goods and services

Additional information

The IFBLS World Congress is held every second year, and Congress Fees are collected from the Host Country as a one-time payment of $30,000.00 CAD.
The IFBLS World Congress was not held in 2023, therefore are no Congress Fees to report in this report.
There were no in-kind donations to report in 2023.
Investment income was earned on Savings and Term Deposit accounts.

Membership

Entity's members

Is the entity you represent membership based?

Yes

Overview of categories and their voting rights in the main governing body:

Total number Voting

Individuals

NGOs

Private sector entities

Philanthropic foundations

Academic institutions

Government entities

Intergovernmental organizations

Organizational Structure

Parent entity

In the register Registered Entity Entity Name

No data available

Yes

Legal status

Affiliated entities (or subsidiaries)

In the register Registered Entity Entity Name

No data available

Relations

Entity's membership in other entities

In the register Registered Entity Entity Name Type of membership

No data available

Members of the entity

In the register Registered Entity Member Name

No data available

Activities

Aims (or purposes, objectives) of the entity as they appear in its constitution or by-laws or equivalent document.

To increase recognition and contributions of Biomedical Laboratory Science to improve global health.

To support, advance and promote good scientific laboratory practice through the development and adherence to high quality standards in diverse environments throughout the world.

To support and promote education and advancement of science and technology in the professional development of Biomedical Laboratory Scientists.

To support, advance and promote ethical and professional values in Biomedical Laboratory Science.

To facilitate the exchange of ideas through development of partnerships within the global healthcare community.

The activities of the entity are related to the following strategic priorities and outcomes of the current WHO's General Programme of Work:

Strategic objective 1: Respond to climate change, an escalating health threat in the 21st century

Joint outcome 1.1. More climate-resilient health systems are addressing health risks and impacts

Joint outcome 1.2. Lower-carbon health systems and societies are contributing to health and well-being

Strategic objective 2: Address health determinants and the root causes of ill health in key policies across sectors

Joint outcome 2.1. Health inequities reduced by acting on social, economic, environmental and other determinants of health

Joint outcome 2.2. Priority risk factors for noncommunicable and communicable diseases, violence and injury, and poor nutrition, reduced through multisectoral approaches

Joint outcome 2.3. Populations empowered to control their health through health promotion programmes and community involvement in decision-making

Strategic objective 3: Advance the primary health care approach and essential health system capacities for universal health coverage

Joint outcome 3.1. The primary health care approach renewed and strengthened to accelerate universal health coverage

Joint outcome 3.2. Health and care workforce, health financing and access to quality-assured health products substantially improved

Joint outcome 3.3. Health information systems strengthened and digital transformation implemented.

Strategic objective 4: Improve health service coverage and financial protection to address inequity and gender inequalities

Joint outcome 4.1. Equity in access to quality services improved for noncommunicable diseases, mental health conditions and communicable diseases, while addressing antimicrobial resistance

Joint outcome 4.2. Equity in access to sexual, reproductive, maternal, newborn, child, adolescent and older person health and nutrition services and immunization coverage improved

Joint outcome 4.3. Financial protection improved by reducing financial barriers and out-of-pocket health expenditures, especially for the most vulnerable

Strategic objective 5: Prevent, mitigate and prepare for risks to health from all hazards

Joint outcome 5.1. Risks of health emergencies from all hazards reduced and impact mitigated

Joint outcome 5.2. Preparedness, readiness and resilience for health emergencies enhanced

Strategic objective 6: Rapidly detect and sustain an effective response to all health emergencies

Joint outcome 6.1. Detection of and response to acute public health threats is rapid and effective

Joint outcome 6.2. Access to essential health services during emergencies is sustained and equitable

Additional information on the entity's activities

Country presence

Countries where the entity has activities, members and regional offices / representatives:

Regions

Countries

Activities

Members

Offices / representatives

African Region

Region of the Americas

Eastern Mediterranean Region

European Region

South-East Asia Region

Western Pacific Region

Global

Disclosure & declaration

Tobacco/Arms related disclosure statement for non-State actors

Pursuant the WHO Framework of Engagement with Non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry. WHO also does not engage with the arms industry.

For the purposes of this statement:

tobacco industry means any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such entity; and
arms industry means any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such entity.

This disclosure statement needs to be provided by any nongovernmental organization, private sector entity, philanthropic foundation and academic institution prior to engaging with WHO.

In view of the foregoing, please answer the following questions:

Is your entity, or was your entity over the last four years, part of the tobacco or arms industries (as defined above)?

Yes

No

Unable to answer

To the best of your entity’s knowledge, is your entity, or has your entity over the last four years, engaged in activities that are aimed at furthering or supporting the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.

Yes

No

Unable to answer

To the best of your entity’s knowledge, does your entity currently, or did your entity over the last four years, have any other association or relationship with the tobacco industry (as defined above). This includes in particular investment interests (other than general mutual funds or similar arrangements whereby your entity has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.

Yes

No

Unable to answer

If you have answered yes to any of the above or are unable to answer one or more questions, please provide a general statement of explanation.

Please note that the WHO Secretariat reserves the right to request additional information from your entity in this regard.

By providing this statement, your entity commits to promptly inform WHO of any change to the above information and to complete a new statement that describes the changes.

Engagement with other industries affecting human health or affected by WHO norm and standards

Does the entity you represent have any formal association, affiliation or links with the following industry sectors?

If yes, please tick the box of the industry concerned and provide details in the space provided:

Alcohol

Chemical

Food and beverages

Health care

IFBLS is an association of associations representing Biomedical Laboratory Sciences.

Pharmaceutical

Others

Please specify industry

WHO Secretariat reserves the right to request additional information from the entity you represent relevant to its engagement with WHO.

*Sexual Exploitation, Abuse and Harassment (SEAH) and Misconduct (abusive or fraudulent)

Entities engaging with WHO are expected to ensure that the conduct of their employees and any other persons engaged by them to perform any activities or to provide any services for WHO on behalf of the entities is consistent with the WHO standards of conduct. In particular, WHO has zero tolerance towards any form of sexual misconduct, which includes sexual exploitation, sexual abuse, sexual violence, and sexual harassment, and other types of abusive or fraudulent conduct. In the view of the forgoing, please confirm that your entity shall:

Take all reasonable and appropriate measures to prevent sexual misconduct as defined in WHO’s Policy on Preventing and Addressing Sexual Misconduct, and other types of abusive or fraudulent conduct as defined, respectively, in WHO’s Policy on Preventing and Addressing Abusive Conduct and in WHO’s Policy on Prevention, Detection and Response to Fraud and Corruption by any of its employees and by any other persons engaged by it to perform any activities or to provide any services for WHO on the entity’s behalf;

Promptly report to WHO’s Office of Internal Oversight Services (IOS) at investigation@who.int any actual or suspected misconduct, as defined by WHO in these Policies and of which the entity becomes aware;

Promptly communicate to IOS any measures that may be necessary or appropriate to protect the confidentiality and wellbeing of the alleged victim;

Promptly respond to any actual or suspected misconduct as defined by WHO in these Policies of which the entity becomes aware; and

To cooperate with IOS and keep IOS informed of the status and outcome of any measures of protection, corrections to operations, investigation, and disciplinary action taken against any perpetrator by the entity.

Date submitted